Takeda to license Novavax’ Covid-19 vaccine candidate NVX‑CoV2373
Novavax has agreed to grant the Japanese licensing rights to NVX‑CoV2373, a vaccine candidate modified from the genetic sequence of the Covid-19 causing SARS‑CoV‑2 virus, to Takeda Pharmaceutical.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.